Simon J. Harrison

11.4k citations

246 papers · 5.6k indexed · 1 hit paper · h-index 38

Impact in

Hematology top 0.2%
- Multiple Myeloma Research and Treatments
Oncology top 1%
- Peptidase Inhibition and Analysis
- CAR-T cell therapy research

Papers in

Hematology 151
- Multiple Myeloma Research and Treatments 139
Oncology 109
- CAR-T cell therapy research 34
- Peptidase Inhibition and Analysis 26
- Cancer Treatment and Pharmacology 21

Co-authors: H. Miles Prince David Ritchie Hang Quach Mark Bishton Paul J. Neeson Mark J. Smyth Monica A. Slavin Benjamin W. Teh
Journals: Blood (55 papers)Journal of Clinical Oncology (16 papers)British Journal of Haematology (9 papers)Haematologica (5 papers)Bone Marrow Transplantation (4 papers)
Partner nations: Australia United States United Kingdom

In The Last Decade

Simon J. Harrison

231 papers receiving 5.5k citations

Hit Papers

align trajectories log scale

Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial 2020 · 256 citations

Peers

Countries citing papers authored by Simon J. Harrison

Since Specialization

Citations

This map shows the geographic impact of Simon J. Harrison's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Simon J. Harrison with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Simon J. Harrison more than expected).

Fields of papers citing papers by Simon J. Harrison

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Simon J. Harrison. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Simon J. Harrison. The network helps show where Simon J. Harrison may publish in the future.

Co-authors

The 25 scholars most cited alongside Simon J. Harrison, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Simon J. Harrison Line = papers co-authored together Simon J. Harrison links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Infections during novel myeloma therapies Leukemia & lymphoma ·Alice Liu, Monica A. Slavin, Simon J. Harrison, Benjamin W. Teh	2024	1
2	Evaluating the cost-effectiveness of polygenic risk score-stratified screening for abdominal aortic aneurysm Nature Communications ·Martin Kelemen, John Danesh, Emanuele Di Angelantonio, Michael Inouye, John D. O’Sullivan, Lisa Pennells, Tarit Roychowdhury, Michael Sweeting, Angela Wood, Simon J. Harrison, Lois G. Kim	2024	3
3	Abstracts Anaesthesia ·G Adkins, Simon Booth, B Rymer, Paul Norris, Gabriel Chow, R Babic, Simon J. Harrison, A Johnstone, Katherine M. Morrison, P. K. Raju, Nhs Tayside, J Whiting, J Sharpe Queen, Chin‐Lee Wu, Rohan N. Shah, A Luton, S El-Ghazali, Ahmad A. Mirza, Ricard Simó, Cheng Ai Ong, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	2023	2
4	Listening to What Matters Most: Consumer Endorsed Patient Reported Outcome Measures (PROMs) for Use in Multiple Myeloma Clinical Trials: A Descriptive Exploratory Study Clinical Lymphoma Myeloma & Leukemia ·Hayley Beer, Holly Chung, Simon J. Harrison, Hang Quach, Rebecca Taylor-Marshall, Laura Jones, Meinir Krishnasamy	2023	0
5	Regulatory T cells hamper the efficacy of T-cell-engaging bispecific antibody therapy Haematologica ·Mika Casey, Carol Lee, Wing Yu Kwok, Soi Cheng Law, Dillon Corvino, Maher K. Gandhi, Simon J. Harrison, Kyohei Nakamura	2023	11
6	A Prospective, Multinational Study of Clinical and Biological Factors Associated with Short Overall Survival in Multiple Myeloma Blood ·Andy Sing Ong Tang, Kihyun Kım, Fiona Chen, Zoe McQuilten, Peter Mollee, Rajeev Rajagopal, Hang Quach, Phoebe Joy Ho, Simon J. Harrison, Andrew Spencer, Wee Joo Chng	2023	1
7	The importance of frailty assessment in multiple myeloma: a position statement from the Myeloma Scientific Advisory Group to Myeloma Australia Internal Medicine Journal ·Shirlene Sim, Anna Kalff, Gina Tuch, Peter Mollee, P. Joy Ho, Simon J. Harrison, Simon Gibbs, H. Miles Prince, Andrew Spencer, Douglas Joshua, Cindy Lee, Silvia Ling, Nick Murphy, Ferenc Szabó, Jeff Szer, N Weber, Christopher Wård, Dipti Talaulikar, Andrew C.W. Zannettino, Hang Quach	2023	6
8	Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis Blood Advances ·Gemma Reynolds, Edward R. Scheffer Cliff, Ghulam Rehman Mohyuddin, Rakesh Popat, Shonali Midha, Melissa Ng, Simon J. Harrison, Aaron S. Kesselheim, Benjamin W. Teh	2023	42
9	A sequential cohort study evaluating single‐agent KappaMab and KappaMab combined with lenalidomide and low‐dose dexamethasone in relapsed and/or refractory kappa light chain‐restricted multiple myeloma (AMaRC 01‐16) British Journal of Haematology ·Andrew Spencer, Anna Kalff, Jake Shortt, Hang Quach, Craig T. Wallington‐Beddoe, John Reynolds, Patricia Walker, Simon J. Harrison, Rosanne Dunn, Cameron Wellard	2023	2
10	Invariant NKT cells dictate antitumor immunity elicited by a bispecific antibody cotargeting CD3 and BCMA Blood Advances ·Mika Casey, Cui Tu, Simon J. Harrison, Kyohei Nakamura	2022	7
11	Review of Myeloma Therapies and Their Potential for Oral and Maxillofacial Side Effects Cancers ·S. Beaumont, Simon J. Harrison, Jeremy Er	2021	1
12	Subgroup analysis of ICARIA‐MM study in relapsed/refractory multiple myeloma patients with high‐risk cytogenetics British Journal of Haematology ·Simon J. Harrison, Aurore Perrot, Adrían Alegre, David Simpson, Ming Chung Wang, Andrew Spencer, Sosana Delimpasi, Cyrille Hulin, Kazutaka Sunami, Thierry Façon, Philip Vlummens, Kwee Yong, Frank Campana, Marlène Inchauspé, Sandrine Macé, Marie‐Laure Risse, Helgi van de Velde, Paul G. Richardson	2021	32
13	A Wolf in Sheep’s clothing: A case report series of oral manifestations of multiple myeloma Australian Dental Journal ·S. Beaumont, Ray Mun Koo, Simon J. Harrison	2020	4
14	First-in-Human RNA Polymerase I Transcription Inhibitor CX-5461 in Patients with Advanced Hematologic Cancers: Results of a Phase I Dose-Escalation Study Cancer Discovery ·Amit Khot, Natalie Brajanovski, Donald P. Cameron, Nadine Hein, Kylee Maclachlan, Elaine Sanij, John K. C. Lim, John Soong, Emma Link, Piers Blombery, Ella R. Thompson, Andrew Fellowes, Karen E. Sheppard, Grant A. McArthur, Richard B. Pearson, Ross D. Hannan, Gretchen Poortinga, Simon J. Harrison	2019	132
15	FDG-PET/CT in managing infection in patients with hematological malignancy: clinician knowledge and experience in Australia Leukemia & lymphoma ·Abby Douglas, Karin Thursky, Leon J. Worth, Simon J. Harrison, Rodney J. Hicks, Monica A. Slavin	2019	6
16	Access, knowledge and experience with fluorodeoxyglucose positron emission tomography/computed tomography in infection management: a survey of Australia and New Zealand infectious diseases physicians and microbiologists Internal Medicine Journal ·Abby Douglas, Karin Thursky, Leon J. Worth, Simon J. Harrison, Rodney J. Hicks, Monica A. Slavin	2018	7
17	Enumeration, functional responses and cytotoxic capacity of MAIT cells in newly diagnosed and relapsed multiple myeloma Scientific Reports ·Nicholas A. Gherardin, Liyen Loh, Lorenztino Admojo, Alexander J. Davenport, Kelden Richardson, Amy J. Rogers, Phillip K. Darcy, Misty R. Jenkins, H. Miles Prince, Simon J. Harrison, Hang Quach, David P. Fairlie, Katherine Kedzierska, James McCluskey, Adam P. Uldrich, Paul J. Neeson, David Ritchie, Dale I. Godfrey	2018	77
18	Novel Combination Therapies with the RNA Polymerase I Inhibitor CX-5461 Significantly Improve Efficacy in Multiple Myeloma Blood ·Kylee Maclachlan, Andrew Cuddihy, Nadine Hein, Carleen Cullinane, Simon J. Harrison, Ross D. Hannan, Gretchen Poortinga	2017	3
19	RNA Polymerase 1 Transcription Inhibitor CX-5461 in Patients with Advanced Hematologic Malignancies: Results of a Phase I First in Human Study Blood ·Amit Khot, Natalie Brajanovski, Donald P. Cameron, Gretchen Poortinga, Elaine Sanij, John Lim, John Soong, Nadine Hein, Emma Link, Richard B. Pearson, Ross D. Hannan, Grant A. McArthur, Simon J. Harrison	2017	2
20	Oseltamivir Resistance in Adult Oncology and Hematology Patients Infected with Pandemic (H1N1) 2009 Virus, Australia Emerging infectious diseases ·Adrian R Tramontana, Biju George, Aeron C. Hurt, Joseph Doyle, Katherine M. Langan, Alistair Reid, Janet M. Harper, Karin Thursky, Leon J. Worth, Dominic E. Dwyer, C. Orla Morrissey, Paul D.R. Johnson, Kirsty Buising, Simon J. Harrison, John F. Seymour, Patricia E. Ferguson, Bin Wang, Justin T. Denholm, Allen Cheng, Monica A. Slavin	2010	92

About Simon J. Harrison

Simon J. Harrison is a scholar working on Hematology, Oncology, Genetics, Pathology and Forensic Medicine and Immunology, having authored 246 papers that have together received 5.6k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (139 papers), Protein Degradation and Inhibitors (54 papers), CAR-T cell therapy research (34 papers), Peptidase Inhibition and Analysis (26 papers), Chronic Lymphocytic Leukemia Research (23 papers), Cancer Treatment and Pharmacology (21 papers), Immune Cell Function and Interaction (18 papers) and Monoclonal and Polyclonal Antibodies Research (17 papers). The work is most often cited by research in Hematology (2.5k citations), Oncology (2.5k citations), Genetics (589 citations), Immunology (855 citations) and Molecular Biology (2.8k citations). Simon J. Harrison has collaborated with scholars based in Australia, United States and United Kingdom. Frequent co-authors include H. Miles Prince, David Ritchie, Hang Quach, Mark Bishton, Paul J. Neeson, Mark J. Smyth, Monica A. Slavin, Benjamin W. Teh, A. Keith Stewart and Andrew Spencer. Their work appears in journals such as Blood, Journal of Clinical Oncology, British Journal of Haematology, Haematologica and Bone Marrow Transplantation.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact